Testing relacorilant plus nab-paclitaxel for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new combination of two drugs—relacorilant and nab-paclitaxel—for women with cervical cancer that has returned or spread after initial chemotherapy and immunotherapy (if they were eligible). The goal is to see if this combination can shrink tumors or slow cancer growth. Participants will receive the study drugs as infusions and will be monitored closely for safety and tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have cervical cancer that has returned or spread.
- You must have had exactly one prior line of platinum-based chemotherapy (with or without bevacizumab).
- If eligible, you must have received immunotherapy (PD-1/PD-L1 inhibitor) for cervical cancer.
- You must have had no more than 3 prior treatments for advanced disease.
- You must not have had weekly paclitaxel before (except as part of your first treatment with a platinum drug).
- Your cancer must be measurable on imaging scans.
- You must be 18 or older and assigned female at birth.
- You must have adequate organ function (kidney, liver, blood counts).
- You must have no significant nerve damage (peripheral neuropathy) from prior treatment.
- You must not have active inflammatory bowel disease.
- You must not have untreated or symptomatic brain metastases.
- You must not have had another cancer in the past 3 years (except certain skin cancers or early-stage cervical/breast cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
This trial tests a combination of chemotherapy (nab-paclitaxel plus cisplatin) given together with radiation therapy for people with locally advanced cervical cancer. The goal is to see if this treatment is safe and effective.
This Phase 2 trial tests cadonilimab (an immunotherapy) combined with nab-paclitaxel (chemo) to treat cervical cancer that has come back or spread and did not respond to prior immune checkpoint medicines. It may help shrink tumors and improve disease control after prior immunotherapy failure.
This trial tests adding a drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) for people with pancreatic cancer that has spread. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.